- Chan, Sarah;
- Belmar, Nicole;
- Ho, Sun;
- Rogers, Bryan;
- Stickler, Marcia;
- Graham, Michelle;
- Lee, Eileen;
- Tran, Ninian;
- Zhang, Dong;
- Gupta, Priyanka;
- Sho, Mien;
- MacDonough, Tracy;
- Woolley, Andrew;
- Kim, Han;
- Zhang, Hong;
- Liu, Wei;
- Zheng, Pingping;
- Dezso, Zoltan;
- Halliwill, Kyle;
- Ceccarelli, Michele;
- Rhodes, Susan;
- Thakur, Archana;
- Forsyth, Charles;
- Xiong, Mengli;
- Tan, Siu;
- Iyer, Ramesh;
- Lake, Marc;
- Digiammarino, Enrico;
- Zhou, Li;
- Bigelow, Lance;
- Longenecker, Kenton;
- Judge, Russell;
- Liu, Cassie;
- Trumble, Max;
- Remis, Jonathan;
- Fox, Melvin;
- Cairns, Belinda;
- Akamatsu, Yoshiko;
- Hollenbaugh, Diane;
- Harding, Fiona;
- Alvarez, Hamsell
Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies have shown limited therapeutic effect, which may be due to suboptimal receptor clustering-mediated signaling. To overcome this potential limitation, a rational protein engineering approach is needed to optimize GITR agonist-based immunotherapies. Here we show a bispecific molecule consisting of an anti-PD-1 antibody fused with a multimeric GITR ligand (GITR-L) that induces PD-1-dependent and FcγR-independent GITR clustering, resulting in enhanced activation, proliferation and memory differentiation of primed antigen-specific GITR+PD-1+ T cells. The anti-PD-1-GITR-L bispecific is a PD-1-directed GITR-L construct that demonstrated dose-dependent, immunologically driven tumor growth inhibition in syngeneic, genetically engineered and xenograft humanized mouse tumor models, with a dose-dependent correlation between target saturation and Ki67 and TIGIT upregulation on memory T cells. Anti-PD-1-GITR-L thus represents a bispecific approach to directing GITR agonism for cancer immunotherapy.